Should I buy or sell Summit Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Summit Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SMMT shares. View SMMT analyst ratings or view top-rated stocks .

What is Summit Therapeutics' stock price target for 2024?

1 brokerages have issued 1 year target prices for Summit Therapeutics' stock. Their SMMT share price targets range from $8.00 to $8.00. On average, they anticipate the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 133.9% from the stock's current price. View analysts price targets for SMMT or view top-rated stocks among Wall Street analysts .

How have SMMT shares performed in 2024?

Summit Therapeutics' stock was trading at $2.61 at the beginning of the year. Since then, SMMT stock has increased by 31.0% and is now trading at $3.42. View the best growth stocks for 2024 here .

Are investors shorting Summit Therapeutics?

Summit Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 21,810,000 shares, an increase of 28.6% from the March 15th total of 16,960,000 shares. Based on an average daily trading volume, of 2,340,000 shares, the short-interest ratio is currently 9.3 days. Currently, 26.3% of the shares of the stock are sold short. View Summit Therapeutics' Short Interest .

When is Summit Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our SMMT earnings forecast .

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics Inc. (NASDAQ:SMMT) released its quarterly earnings results on Tuesday, February, 20th. The company reported ($0.05) earnings per share (EPS) for the quarter. The firm had revenue of $0.20 million for the quarter.

What ETFs hold Summit Therapeutics' stock?

ETFs with the largest weight of Summit Therapeutics (NASDAQ:SMMT) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO) and Range Cancer Therapeutics ETF (CNCR) . Virtus LifeSci Biotech Clinical Trials ETF (BBC) .

What other stocks do shareholders of Summit Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Summit Therapeutics investors own include Energy Transfer (ET) , Summit Therapeutics (SUMM) , Sarepta Therapeutics (SRPT) , Gilead Sciences (GILD) , CBL & Associates Properties (CBL) , SandRidge Permian Trust (PER) , Cornerstone Total Return Fund (CRF) , Ford Motor (F) and Martin Midstream Partners (MMLP) .

When did Summit Therapeutics IPO?

Summit Therapeutics (SMMT) raised $40 million in an IPO on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. acted as the underwriters for the IPO and Needham was co-manager.

Who are Summit Therapeutics' major shareholders?

Summit Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wealth Management Partners LLC (0.01%). Insiders that own company stock include Ankur Dhingra , Mahkam Zanganeh , Maky Zanganeh , Manmeet Singh Soni and Robert W Duggan . View institutional ownership trends .

How do I buy shares of Summit Therapeutics?

Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SMMT

Summit Therapeutics (SMMT) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free SMMT Stock Alerts

$3.50

-0.01 (-0.28%)

(As of 05:21 PM ET)

Compare

Today's Range: $3.34
▼
$3.55
50-Day Range: $3.28
▼
$5.07
52-Week Range: $1.30
▼
$5.22

Volume: 1.73 million shs
Average Volume: 2.23 million shs
Market Capitalization: $2.46 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

Get Summit Therapeutics alerts:

Summit Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 133.9% Upside
$8.00 Price Target
Short Interest: Bearish
26.25% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.73
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$487,500 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.24) to ($0.29) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.98 out of 5 stars

Medical Sector

536th out of 918 stocks

Pharmaceutical Preparations Industry

244th out of 419 stocks

3.5

Analyst's Opinion

Consensus Rating
Summit Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Summit Therapeutics has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
26.25% of the float of Summit Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Summit Therapeutics has a short interest ratio ("days to cover") of 9.3.
Change versus previous month
Short interest in Summit Therapeutics has recently increased by 28.60%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Summit Therapeutics does not currently pay a dividend.
Dividend Growth
Summit Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SMMT.

3.2

News and Social Media Coverage

News Sentiment
Summit Therapeutics has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Summit Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 13 people have searched for SMMT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
13 people have added Summit Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 44% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Summit Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $487,500.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
83.70% of the stock of Summit Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 4.61% of the stock of Summit Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Summit Therapeutics are expected to decrease in the coming year, from ($0.24) to ($0.29) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Summit Therapeutics is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Summit Therapeutics is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Summit Therapeutics has a P/B Ratio of 31.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Summit Therapeutics Stock (NASDAQ:SMMT)

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

SMMT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SMMT Stock News Headlines

March 29, 2024 | insidertrades.com

Insider Buying: Summit Therapeutics Inc. (NASDAQ:SMMT) CEO Acquires 30,000 Shares of Stock

April 15, 2024 | americanbankingnews.com

Short Interest in Summit Therapeutics Inc. (NASDAQ:SMMT) Rises By 28.6%

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

April 14, 2024 | americanbankingnews.com

Summit Therapeutics (NASDAQ:SMMT) Trading Down 6.7%

April 11, 2024 | finance.yahoo.com

Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors

April 11, 2024 | businesswire.com

Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors

April 10, 2024 | businesswire.com

Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum

April 9, 2024 | reuters.com

Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 9, 2024 | prnewswire.com

Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer

March 29, 2024 | investing.com

Summit Therapeutics CEO acquires shares worth over $411k

March 29, 2024 | fool.com

Why Summit Therapeutics Stock Crushed the Market This Week

March 14, 2024 | businesswire.com

Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024

March 11, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT

March 5, 2024 | businesswire.com

Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference

March 3, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT

February 27, 2024 | msn.com

SHAREHOLDER ALERT: Potential Recovery for Summit Therapeutics Inc. (SMMT) Investors

February 26, 2024 | businesswire.com

Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

February 21, 2024 | uk.finance.yahoo.com

Summit Therapeutics plc (SMMT)

February 21, 2024 | finance.yahoo.com

Q4 2023 Summit Therapeutics Inc Earnings Call

February 21, 2024 | finance.yahoo.com

Summit Therapeutics Inc. (NASDAQ:SMMT) Q4 2023 Earnings Call Transcript

February 20, 2024 | finance.yahoo.com

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023

February 20, 2024 | finance.yahoo.com

Summit Therapeutics Inc (SMMT) Reports Comprehensive 2023 Financial Results and Clinical ...

February 20, 2024 | businesswire.com

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023

February 17, 2024 | finance.yahoo.com

SMMT Mar 2024 4.000 put

February 17, 2024 | finance.yahoo.com

SMMT Apr 2024 3.000 call

February 14, 2024 | businesswire.com

Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024

See More Headlines

Receive SMMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/20/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:SMMT
CUSIP: N/A
CIK: 1599298
Web: www.summitplc.com
Phone: 650-460-8308
Fax: 44-12-3544-3999
Employees: 105
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.00
High Stock Price Target: $8.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +127.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.53)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-614,930,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -87.45%
Return on Assets: -41.17%

Debt

Debt-to-Equity Ratio: 1.29
Current Ratio: 9.30
Quick Ratio: 9.30

Sales & Book Value

Annual Sales: $700,000.00
Price / Sales: 3,528.56
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.11 per share
Price / Book: 32.00

Miscellaneous

Outstanding Shares: 701,703,000
Free Float: 114,378,000
Market Cap: $2.47 billion
Optionable: Optionable
Beta: -1.21

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Robert W. Duggan (Age 79)
Co-CEO & Executive Chairman
Dr. Mahkam Zanganeh D.D.S. (Age 54)
M.B.A., Co-CEO, President & Director
Comp: $657.81k
Mr. Ankur Dhingra (Age 47)
Chief Financial Officer
Comp: $530k
Mr. Manmeet Singh Soni (Age 46)
COO & Director
Comp: $591.5k
Prof. Dame Kay Davies DBE (Age 73)
FRS CBE, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor
Ms. Abby Guzman Murphy
Head of Human Resources
Ms. Divya Chari (Age 56)
Head of Global Clinical Operations
Mr. Dave Gancarz
Chief Business & Strategy Officer?
Mr. Will Black
Head of Information Technology?
Dr. Betty Y. Chang Ph.D.
Head of Research, Oncology & Inflammation?

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SMMT Stock Analysis - Frequently Asked Questions

Should I buy or sell Summit Therapeutics stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Summit Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SMMT shares.
View SMMT analyst ratings or view top-rated stocks.
What is Summit Therapeutics' stock price target for 2024?: 1 brokerages have issued 1 year target prices for Summit Therapeutics' stock. Their SMMT share price targets range from $8.00 to $8.00. On average, they anticipate the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 133.9% from the stock's current price.
View analysts price targets for SMMT or view top-rated stocks among Wall Street analysts.
How have SMMT shares performed in 2024?: Summit Therapeutics' stock was trading at $2.61 at the beginning of the year. Since then, SMMT stock has increased by 31.0% and is now trading at $3.42.
View the best growth stocks for 2024 here.
Are investors shorting Summit Therapeutics?: Summit Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 21,810,000 shares, an increase of 28.6% from the March 15th total of 16,960,000 shares. Based on an average daily trading volume, of 2,340,000 shares, the short-interest ratio is currently 9.3 days. Currently, 26.3% of the shares of the stock are sold short.
View Summit Therapeutics' Short Interest.
When is Summit Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our SMMT earnings forecast.
How were Summit Therapeutics' earnings last quarter?: Summit Therapeutics Inc. (NASDAQ:SMMT) released its quarterly earnings results on Tuesday, February, 20th. The company reported ($0.05) earnings per share (EPS) for the quarter. The firm had revenue of $0.20 million for the quarter.

What ETFs hold Summit Therapeutics' stock?: ETFs with the largest weight of Summit Therapeutics (NASDAQ:SMMT) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO) and Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).
What other stocks do shareholders of Summit Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Summit Therapeutics investors own include Energy Transfer (ET), Summit Therapeutics (SUMM), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), CBL & Associates Properties (CBL), SandRidge Permian Trust (PER), Cornerstone Total Return Fund (CRF), Ford Motor (F) and Martin Midstream Partners (MMLP).
When did Summit Therapeutics IPO?: Summit Therapeutics (SMMT) raised $40 million in an IPO on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. acted as the underwriters for the IPO and Needham was co-manager.
Who are Summit Therapeutics' major shareholders?: Summit Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wealth Management Partners LLC (0.01%). Insiders that own company stock include Ankur Dhingra, Mahkam Zanganeh, Maky Zanganeh, Manmeet Singh Soni and Robert W Duggan.
View institutional ownership trends.
How do I buy shares of Summit Therapeutics?: Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SMMT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial